---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093991"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:18:11.372093+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs

## Summary
- Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.
- Cash, equivalents & marketable securities $99.3M; sufficient into H2 2025; $45M SVB credit facility available, undrawn.
- TN-201 received FDA Rare Pediatric Disease Designation for MYBPC3-associated HCM; interim Phase 1b data expected H2 2024.
- TN-401 cleared by UK MHRA to start Phase 1b; 84% of screening volunteers eligible based on low AAV9 antibodies.
- CFO Leone Patterson departing Aug 14; CEO Faraz Ali interim PFO; Chihiro Saito interim PAO.

## SEC filing metadata
- accession: 0000950170-24-093991
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/tnya-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093991
- JSON: https://secwatch.observer/filing/0000950170-24-093991.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093991.txt

## Key facts
- Executive change
  Chihiro Saito was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Principal Accounting Officer
  source text: Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm
- Executive change
  Faraz Ali was appointed as Interim Principal Financial Officer at Tenaya Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Principal Financial Officer
  source text: Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm
- Executive change
  Leone Patterson departed as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..
  - Action: ceasing to be
  - Role: Chief Financial and Business Officer
  source text: Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017024093991/0000950170-24-093991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.